GSK GlaxoSmithKline
- 39.565
- -0.445-1.11%
GlaxoSmithKline News
6-K: Gsk Makes a Strong Start to 2024 with Improving Outlook for the Year
GlaxoSmithKline | 6-K: Glaxosmithkline 2023 Annual Report on Form 20-F
GlaxoSmithKline | 20-F: Registration statement / Annual report / Transition report
GlaxoSmithKline | 6-K: Gsk Delivers Strong 2023 Performance and Upgrades Growth Outlooks
GlaxoSmithKline | 6-K: Strong Year-to-Date and Q3 Performance Drives Upgrade to Full-Year Guidance
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 20-F: FY2022 Annual Report
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 20-F: FY2021 Annual Report
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 6-K: Report of foreign private issuer (related to financial reporting)
GlaxoSmithKline | 20-F: FY2020 Annual Report
Analysis
Price Target
No Data
